sglt2 inhibitors vs glp-1 agonists Receptor Agonist Therapy With and Without in Patients With Type 2 Diabetes Effect of combination treatment with

S2: Peptide Hormones and Growth Factors - New EPO Mimetic Pegmolesatide was added as a new erythropoietin (EPO) mimetic agent

Key Takeaways: GLP-1 medications are approved in India for managing type 2 diabetes and, in some cases, weight management

Sensitivity analyses Figure 3 shows the results of the one-way sensitivity analyses

GLP1-RAs have been shown to have action in the central nervous system that mediates their weight loss and appetite suppressant effects 53,54

Instead, the Lancet Commission is looking to define more appropriate, scientifically sound and pragmatic criteria for the diagnosis of clinical obesity as a disease state, not a risk factor

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis